Recently, the Falexpand® HP PTA Balloon Catheter, independently developed by Kossel Medtech (Suzhou) Co., Ltd., was approved by the National Medical Products Administration (NMPA).
Falexpand® HP PTA Balloon Catheter is suitable for percutaneous transluminal angioplasty (PTA) of the peripheral vascular system, including iliac, femoral, popliteal, tibial, peroneal, and renal arteries, and for the treatment of blocked arteriovenous fistulas for natural or artificial dialysis.
Percutaneous transluminal angioplasty (PTA) is widely used as a routine method to solve the stenosis of the vascular pathway, and the high-pressure balloon is the core instrument of PTA treatment. Compared with the PTA balloon catheter, the high-pressure balloon catheter has higher filling pressure, can effectively dilate the intractable stenosis lesions, and has lower compliance, which can effectively reduce the incidence of vascular dissection.
The acquisition of the medical device registration certificate is conducive to enriching the product categories of Kessel Medical, further improving the product layout in the field of peripheral intervention, continuously meeting the diversified clinical needs, and further enhancing the company’s core competitiveness.